A Randomised Controlled Trial of Bumetanide in the Treatment of Autism in Children

DSpace/Manakin Repository

A Randomised Controlled Trial of Bumetanide in the Treatment of Autism in Children

Citable link to this page


Title: A Randomised Controlled Trial of Bumetanide in the Treatment of Autism in Children
Author: Lemonnier, Éric; Degrez, Céline; Phelep, Morgane; Tyzio, Roman; Josse, Florent; Grandgeorge, Marine; Hadjikhani, Nouchine; Ben-Ari, Yehezkel

Note: Order does not necessarily reflect citation order of authors.

Citation: Lemonnier, Éric, Céline Degrez, Morgane Phelep, Roman Tyzio, Florent Josse, Marine Grandgeorge, Nouchine Hadjikhani, and Yehezkel Ben-Ari. 2012. A randomised controlled trial of bumetanide in the treatment of autism in children. Translational Psychiatry 2(12): e202.
Full Text & Related Files:
Abstract: Gamma aminobutyric acid (GABA)-mediated synapses and the oscillations they orchestrate are altered in autism. GABA-acting benzodiazepines exert in some patients with autism paradoxical effects, raising the possibility that like in epilepsies, GABA excites neurons because of elevated intracellular concentrations of chloride. Following a successful pilot study, we have now performed a double-blind clinical trial using the diuretic, chloride-importer antagonist bumetanide that reduces intracellular chloride reinforcing GABAergic inhibition. Sixty children with autism or Asperger syndrome (3–11 years old) received for 3 months placebo or bumetanide (1 mg daily), followed by 1-month wash out. Determination of the severity of autism was made with video films at day 0 (D0) and D90 by blind, independent evaluators. Bumetanide reduced significantly the Childhood Autism Rating Scale (CARS) (D90−D0; P<0.004 treated vs placebo), Clinical Global Impressions (P<0.017 treated vs placebo) and Autism Diagnostic Observation Schedule values when the most severe cases (CARS values above the mean±s.d.; n=9) were removed (Wilcoxon test: P-value=0.031; Student's t-test: P-value=0.017). Side effects were restricted to an occasional mild hypokalaemia \((3.0–3.5 mM l^{−1} K^{+})\) that was treated with supplemental potassium. In a companion study, chronic bumetanide treatment significantly improved accuracy in facial emotional labelling, and increased brain activation in areas involved in social and emotional perception (Hadjikhani et al., submitted). Therefore, bumetanide is a promising novel therapeutic agent to treat autism. Larger trials are warranted to better determine the population best suited for this treatment.
Published Version: doi:10.1038/tp.2012.124
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3565189/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:10613647
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)


Search DASH

Advanced Search